MENADIONE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Menadione, and what generic alternatives are available?
Menadione is a drug marketed by Lilly and is included in one NDA.
The generic ingredient in MENADIONE is menadione. There is one drug master file entry for this compound. Additional details are available on the menadione profile page.
Summary for MENADIONE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 159 |
Clinical Trials: | 5 |
Patent Applications: | 3,201 |
Formulation / Manufacturing: | see details |
DailyMed Link: | MENADIONE at DailyMed |
Recent Clinical Trials for MENADIONE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Scotmann Pharmaceuticals | Phase 3 |
University of Health Sciences Lahore | Phase 3 |
Tanta University | Phase 1 |
Anatomical Therapeutic Chemical (ATC) Classes for MENADIONE
US Patents and Regulatory Information for MENADIONE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lilly | MENADIONE | menadione | TABLET;ORAL | 002139-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |